Targeted recruitment using cerebrospinal fluid biomarkers: Implications for Alzheimer's disease therapeutic trials

Journal of Alzheimer's Disease

Volumn 34, Issue 2, 2013, Pages 431-437

  Barnes, Josephine ^a   Bartlett, Jonathan W ^a,b   Fox, Nick C ^a   Schott, Jonathan M ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid; clinical trial; magnetic resonance imaging; mild cognitive impairment; patient recruitment

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4;

AGED; ARTICLE; BRAIN ATROPHY; BRAIN VENTRICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84874294259     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121936     Document Type: Article

References (28)

1. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, GreggKM,Liu E, Lieberburg I, Schenk D, Black R, Grundman M (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurol 73, 2061-2070
2. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients withADin an interrupted trial. Neurol 64, 1553-1562 (Pubitemid 40617691)
3. Mitchell AJ, Shiri-Feshki M (2009) Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 119, 252-265
4. Jicha GA, Parisi JE, DicksonDW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63, 674-681
5. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746 (Pubitemid 47058377)
6. Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D (2013) Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging 34, 62-72
7. Lorenzi M, Donohue M, Paternico D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB (2010) Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging 31, 1443-1451
8. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128
9. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of A beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurol 64, 1563-1572 (Pubitemid 40617692)
10. Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC (2010) Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: Baseline adjustment. Neurobiol Aging 31, 1452-1462
11. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CRJ, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ, Alzheimer's Disease Neuroimaging, Initiative (2011) The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 8(1 Suppl), S1-S68
12. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L (2005) Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 1, 55-66 (Pubitemid 43348857)
13. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413
14. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR Jr, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW (2010) Clinical core of the Alzheimer's Disease Neuroimaging Initiative: Progress and plans. Alzheimers Dement 6, 239-246
15. Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR Jr, Weiner MW, Fox NC, Ourselin S (2010) Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection. Neuroimage 50, 516-523
16. McEvoy LK, Edland SD, Holland D, Hagler DJ Jr, Roddey JC, Fennema-Notestine C, Salmon DP, Koyama AK, Aisen PS, Brewer JB, Dale AM (2010) Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord 24, 269-277
17. Schott JM, Bartlett JW, Fox NC, Barnes J (2010) Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol 68, 825-834
18. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH (2010) The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement 6, 257-264
19. Kohannim O, Hua X, Hibar DP, Lee S, Chou YY, Toga AW, Jack CR Jr, Weiner MW, Thompson PM (2010) Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging 31, 1429-1442
20. Donohue MC, Gamst AC, Aisen PS (2011) Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 7, 245-246
21. Maitournam A, Simon R (2005) On the efficiency of targeted clinical trials. Stat Med 24, 329-339 (Pubitemid 40227650)
22. Schneider LS, Kennedy RE, Cutter GR (2010) Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 6, 367-377
23. Schneider LS, Kennedy RE (2011) Estimating power with effect size versus slope differences: Both means and variance matter. Alzheimers Dement 7, 247-249
24. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS,Weiner M, Petersen RC, Jack CR Jr (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67, 308-316
25. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106, 6820-6825
26. Fox NC, Cousens S, Scahill R, Harvey RJ, RossorMN(2000) Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: Power calculations and estimates of sample size to detect treatment effects. Arch Neurol 57, 339-344 (Pubitemid 30140520)
27. Holland D, McEvoy LK, Dale AM (2012) Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp 33, 2586-2602
28. Reiman EM, Langbaum JB, Tariot PN (2010) Alzheimer's prevention initiative: A proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 4, 3-14